2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow Diffuse Large B-cell-lymphoma: new trials by email Literature Review of Diffuse Large B-cell-lymphoma trials Research Report on Diffuse Large B-cell-lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD30 Imaging in Diffuse Large B-cell Lymphoma Brentuximab vedotin - Diffuse Large B-cell-lymphoma | Phase 3 | Unknown | University Medical Center Groningen | 20 | 2024-01-01 | 2024-01-02 |
| High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®), Arm B (TEPADINA®-CARMUBRIS®-Busilvex®) - Diffuse Large B-cell-lymphoma | Phase 3 | Unknown | University Hospital Freiburg | 250 | 2014-07-01 | 2015-08-25 |
Dendritic Cell Sarcoma, Interdigitating (2)
Hemic and Lymphatic Diseases (2) · Histiocytic Disorders, Malignant (2) · Histiocytosis (2) · Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
University Hospital Freiburg (1) · University Medical Center Groningen (1)
Germany (1)
Gerald Illerhaus, PhD (1) · Marcel Nijland, MD (1)
PMID 16864853, PMID 18166803, PMID 18413641, PMID 21745167, PMID 22473593, PMID 27098429, PMID 42486133